Amendment Flag
Current Fiscal Year End Date
Document Period End Date
Entity [Domain]
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Legal Entity [Axis]
Document Type
Award Type [Axis]
Summary of significant accounting policies [Abstract]
Accounting Standards Update 2016-09 [Member]
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net
Accounts Receivable, Net, Current
Accounts payable
Accounts Payable, Current
Legal Entity of Counterparty, Type [Axis]
Billing Status, Type [Axis]
Accrued expenses and other current liabilities
Income taxes payable, net of current
Accumulated other comprehensive loss
Less: Accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated Other Comprehensive Loss [Member]
Intangible assets, weighted average useful life
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Additional Paid-in Capital [Member]
Additional paid-in capital
Accumulated Amortization [Abstract]
Adjustments to reconcile to net cash provided by (used in) operating activities:
Adjustments for New Accounting Pronouncements [Axis]
Total stock-based compensation expense
Allocated Share-based Compensation Expense
Amortization of debt issuance costs, net of tax
Amortization
Amortization of Intangible Assets
Antidilutive Securities [Axis]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Antidilutive shares excluded from calculation (in shares)
ASSETS
Assets [Abstract]
Total assets
Long-lived assets
Current assets:
Total current assets
Assets, Current
Base Rate [Member]
Billed [Member]
Buildings, Building Improvements and Leasehold Improvements [Member]
Building Improvements [Member]
Building Improvements [Member]
Buildings [Member]
Building [Member]
Acquired intangible asset
Business Acquisition, Acquiree [Domain]
Business Acquisition [Axis]
Fair value of contingent purchase consideration
Acquisitions [Abstract]
Business Acquisition [Line Items]
Total purchase price
Fair value adjustment for contingent obligations
Capitalized transaction costs
Summary of total purchase price [Abstract]
Property, plant and equipment
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment
Total fair value of tangible assets acquired and liabilities assumed
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Acquisitions
Inventory
Fair value of tangible assets acquired and liabilities assumed [Abstract]
Transaction costs related to acquisition
Business Combination, Acquisition Related Costs
Canada Revenue Agency [Member]
Purchases of property, plant and equipment unpaid at year end
Cash and cash equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Cash and Cash Equivalents, at Carrying Value
Net (decrease) increase in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Net cash used in investing activities
Net cash used in operating activities
Cash Provided by (Used in) Operating Activities, Discontinued Operations
Net cash provided by financing activities
Cash Provided by (Used in) Financing Activities, Discontinued Operations
Commitments and contingencies
Litigation [Abstract]
$0.001 Par Value Common Stock [Member]
Common Stock [Member]
Common stock, shares authorized (in shares)
Common stock, shares issued (in shares)
Common stock, par value (in dollars per share)
Common stock [Abstract]
Common stock, $0.001 par value; 200,000,000 shares authorized, 50,619,808 shares issued and 49,405,365 shares outstanding at December 31, 2017; 40,996,890 shares issued and 40,574,060 shares outstanding at December 31, 2016
Common stock, voting rights
Balance (in shares)
Balance (in shares)
Common stock, shares outstanding (in shares)
401(k) savings plan [Abstract]
Significant components of provision for income taxes attributable to operations [Abstract]
Net deferred tax asset (liability) [Abstract]
Components of Deferred Tax Assets and Liabilities [Abstract]
Comprehensive income
Comprehensive income
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Software [Member]
Concentration Risk Benchmark [Axis]
Concentration Risk Type [Domain]
Concentration Risk Type [Axis]
Concentrations of credit risk and uncertainties
Concentration Risk Benchmark [Domain]
Concentration risk percentage
Concentration Risk, Percentage
Basis of presentation and consolidation
Construction-in-progress [Member]
Contracts and grants
Cost of product sales and contract manufacturing
Cost of Product Sales [Member]
Cost of Sales [Member]
Credit Facility [Domain]
Credit Facility [Axis]
Total current
Current Income Tax Expense (Benefit)
State
International
Current [Abstract]
Federal
HHS [Member]
Debt instrument amortization period
Debt Instrument [Axis]
Debt Instrument [Axis]
Conversion price per share (in dollars per share)
Debt instrument, basis spread on variable rate
Long-term debt
Debt Disclosure [Text Block]
Long-term debt [Abstract]
Maturity date
Interest rate percentage
Interest rate, stated percentage
Schedule of Long-term Debt Instruments [Table]
Long-Term Debt [Line Items]
Debt Instrument [Line Items]
Face amount of debt instrument
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Intangible assets
Deferred Tax Assets, Goodwill and Intangible Assets
International
Deferred Foreign Income Tax Expense (Benefit)
Debt issuance costs
Federal
Deferred Federal Income Tax Expense (Benefit)
Income taxes
Deferred Income Tax Expense (Benefit)
Deferred tax liability
Deferred Tax Liabilities, Gross
Deferred [Abstract]
Deferred revenue, net of current portion
Deferred revenue, current portion
Deferred Revenue, Current
State
Deferred State and Local Income Tax Expense (Benefit)
Other
Federal losses carryforward
Inventory reserves
Net deferred tax (liabilities)/ asset
Deferred Tax Assets, Net
Deferred tax asset
Deferred Tax Assets, Gross
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance
Foreign deferrals
Deferred Tax Assets, Operating Loss Carryforwards, Foreign
Valuation allowance
Deferred tax assets, valuation allowance
Stock compensation
Research and development carryforward
Fixed assets
Deferred Tax Liabilities, Property, Plant and Equipment
Intangible assets
Deferred Tax Liabilities, Intangible Assets
Deferred tax liabilities, net
Deferred Tax Liabilities, Net
Other
Deferred Tax Liabilities, Other
Matching of qualified deferrals by employer, maximum
Matching contributions made by employer
Depreciation and amortization
Loss from discontinued operations before benefit from income taxes
Net income (loss) per share from discontinued operations-diluted (in dollars per share)
Net loss per share from discontinued operations-diluted (in dollars per share)
Net loss per share-diluted from discontinued operations (in dollars per share)
Discontinued operations [Abstract]
Benefit from income taxes
Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal
TSA revenue from Aptevo
Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue
Net loss from discontinued operations
Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax
Net loss per share from discontinued operations-basic (in dollars per share)
Net loss per share from discontinued operations-basic (in dollars per share)
Net loss per share from discontinued operations-basic (in dollars per share)
Cost of product sales
Other income (expense), net
Disposal Group, Including Discontinued Operation, Other Expense
Loss from operations
Disposal Group, Including Discontinued Operation, Operating Income (Loss)
Disposal Group Name [Domain]
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Discontinued operations
Total revenues
Disposal Group, Including Discontinued Operation, Revenue
Net income (loss) per share - basic:
Net income per share-diluted (in dollars per share)
Earnings Per Share, Diluted
Earnings per share
Earnings Per Share [Text Block]
Net income (loss) per share - diluted:
Net income per share-basic (in dollars per share)
Earnings Per Share, Basic
Earnings per share
Earnings per share [Abstract]
Earnings Per Share [Abstract]
Effect of exchange rate changes on cash and cash equivalents
Federal corporate tax rate
Effective annual tax rate
Compensation cost expected to be recognized related to unvested equity awards
Stock Options [Member]
Weighted average period expected to be recognized related to unvested equity awards
Accrued compensation
Employee-related Liabilities, Current
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Equity Component [Domain]
Eurocurrency [Member]
Excess tax benefits from stock-based compensation
Excess tax benefits from stock-based compensation
Excess Tax Benefit from Share-based Compensation, Operating Activities
Additions
Fair value of measurements
Present value discount rate
Fair Value Inputs, Discount Rate
Fair Value, Hierarchy [Axis]
Measurement Frequency [Axis]
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Balance, beginning of period
Balance, end of period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement Frequency [Domain]
Fair value measurements [Abstract]
Transfers in/(out) of Level 3
Fair Value, Measurements, Recurring [Member]
Fair Value Hierarchy [Domain]
Fair value measurements
Fair Value Disclosures [Text Block]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
Unobservable Input Reconciliation [Roll Forward]
(Income) expense included in earnings
Purchases, sales and issuances
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
Federal Funds Rate [Member]
Federal Funds Effective Swap Rate [Member]
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Net book value of intangible assets
Finite-Lived Intangible Assets, Net
2018
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Ending balance
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets by Major Class [Axis]
2020
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Amortization period of intangible asset
2021
Finite-Lived Intangible Assets, Amortization Expense, Year Four
Intangible Assets, Beginning Balance
Intangible Assets, Ending Balance
Finite-Lived Intangible Assets, Gross
2019
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Finite-Lived Intangible Assets, Major Class Name [Domain]
Foreign currencies
United Kingdom Tax Authority [Member]
Foreign Tax Authority [Member]
Furniture and Equipment [Member]
Furniture and Fixtures [Member]
United States [Member]
Intangible assets and goodwill
Goodwill
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill
Goodwill
Goodwill, Additions
Goodwill, Acquired During Period
Goodwill [Roll Forward]
Goodwill, Beginning Balance
Goodwill, Ending Balance
Goodwill, Gross
Intangible assets and goodwill [Abstract]
U.S. Government [Member]
Income (loss) from operations
Abandonment of equipment charge
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss
Impairment of intangible assets (including IPR&D)
Impairment and abandonment of long-lived assets
Intangible assets and long-lived assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Acquisitions
In Process Research and Development, Policy [Policy Text Block]
Income taxes [Abstract]
Net income per share from continuing operations-basic (in dollars per share)
Net income per share from continuing operations-basic (in dollars per share)
Net income (loss) per share from continuing operations-basic (in dollars per share)
US
Earnings before taxes on income
Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
International
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Federal income tax year selected for audit
Income Statement Location [Axis]
Income Statement Location [Axis]
Income Tax Authority [Axis]
Income Tax Authority [Axis]
Income from continuing operations before provision for income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Net income from continuing operations-diluted (in dollars per share)
Net income per share from continuing operations-diluted (in dollars per share)
Net income per share-diluted from continuing operations (in dollars per share)
Income Statement Location [Domain]
Net loss from discontinued operations
Net loss from discontinued operations
Consolidated Statements of Operations [Abstract]
Income taxes
Income Tax Disclosure [Text Block]
Income Tax Contingency [Line Items]
Income Tax Authority [Domain]
Income Tax Authority [Domain]
Disposal Groups, Including Discontinued Operations [Table]
Income Tax Contingency [Table]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group Name [Axis]
Federal tax at statutory rates
Impact of foreign operations
Income tax reconciliation [Abstract]
Change in U.S. Tax Rate
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount
Change in valuation allowance
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Provision for income taxes
Total provision for income taxes
Income tax expense (benefit)
Stock Compensation
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount
Other differences
Net income from continuing operations
Net Income from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Income tax receivable, net
State taxes, net of federal benefit
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
Cash paid during the year for income taxes
Income taxes
Tax credits
Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Accrued expenses and other liabilities
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accounts payable
Income taxes
Increase (Decrease) in Income Taxes Receivable
Accrued compensation
Increase (decrease) in deferred revenue
Deferred revenue
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Inventories
Increase (Decrease) in Inventories
Decrease in unbilled accounts receivable
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Dilutive securities-equity awards (in shares)
Dilutive securities-convertible debt (in shares)
Intangible Assets [Abstract]
Intangible assets, net
Intangible Assets, Net (Excluding Goodwill)
Cost Basis [Abstract]
Capitalized interest
Interest Capitalization, Policy [Policy Text Block]
Capitalized interest [Abstract]
Interest costs incurred
Interest costs capitalized
Interest expense, net of tax
Interest expense
Interest Expense
Cash paid during the year for interest
U.S. Federal Tax Authority [Member]
Internal Revenue Service (IRS) [Member]
Inventories
Inventory Disclosure [Text Block]
Finished goods
Inventories
Total inventories
Inventory, Net
Inventories [Abstract]
Work-in-process
Raw materials and supplies
Inventories
Interest income
Letter of credit, outstanding amount
Land and Improvements [Member]
Operating lease expiration date
Leasehold Improvements [Member]
Leases
Leases of Lessee Disclosure [Text Block]
Leases [Abstract]
Legal Entity Type of Counterparty [Domain]
Litigation
Total liabilities and stockholders' equity
Liabilities and Equity
Total liabilities
Liabilities
LIABILITIES AND STOCKHOLDERS' EQUITY
Total current liabilities
Liabilities, Current
Current liabilities:
Current borrowing capacity
Commitment fee percentage
Outstanding credit facility
Maximum borrowing capacity
Line of Credit Facility, Maximum Borrowing Capacity
Accounts receivable
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]
Long-term indebtedness
Long-term Debt, Excluding Current Maturities
Significant customers and accounts receivable
Maximum [Member]
Minimum [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Nature of the business and organization
Nature of Operations [Text Block]
Net increase (decrease) in cash and cash equivalents
Net Cash Provided by (Used in) Discontinued Operations
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Cash flows from financing activities:
Cash flows from investing activities:
Cash flows from operating activities:
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Numerator [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
Net income
Net income
Net income
Net Income (Loss) Attributable to Parent
New Accounting Pronouncements or Change in Accounting Principle [Table]
Offsetting reduction in retained earnings
Recently issued accounting standards
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total other expense, net
Nonoperating Income (Expense)
Other income (expense):
Notes payable
Number of business segments
Number of reportable segments
Noncontrolling Interest in Subsidiary [Member]
Open tax year
Operating expenses:
Minimum lease receipts
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals
Operating loss carryforwards, expiration year
2022 and beyond
2018
Total lease expense
Future minimum lease payments under operating lease [Abstract]
Total minimum lease payments
Operating Leases, Future Minimum Payments Due
2017
2021
2020
Income from operations
Operating Income (Loss)
2019
Operating Leased Assets [Line Items]
Net operating loss carryforwards
Operating Loss Carryforwards [Table]
Operating Loss Carryforwards [Line Items]
Nature of the business and organization [Abstract]
Foreign currency translations, net of tax
Foreign currency translation, net of tax
Other Costs [Member]
Other
Other Noncash Income (Expense)
Other assets
Depreciation and amortization
Other Depreciation and Amortization
Other liabilities
Other income (expense), net
Supplemental information on non-cash investing and financing activities:
Products and Services [Domain]
Taxes paid on behalf of employees for equity activity
Payments Related to Tax Withholding for Share-based Compensation
Debt issuance costs
Payments of Debt Issuance Costs
Amount paid
Payments for Restructuring
Purchase of treasury stock
Payments for Repurchase of Common Stock
Acquisitions
Payments to Acquire Businesses, Net of Cash Acquired
Amount of cash paid to Sanofi
Payments to Acquire Businesses, Gross
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
401(k) savings plan
Pension and Other Postretirement Benefits Disclosure [Text Block]
Plan Name [Axis]
Plan Name [Domain]
Preferred stock [Abstract]
Preferred stock, par value (in dollars per share)
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both December 31, 2017 and December 31, 2016
Preferred stock, shares issued (in shares)
Preferred stock, shares outstanding (in shares)
Preferred stock, shares authorized (in shares)
Prepaid expenses and other current assets
Restricted cash
Proceeds from (Repayments of) Restricted Cash, Financing Activities
Proceeds from long-term debt obligations
Proceeds from Issuance of Long-term Debt
Issuance of common stock upon exercise of stock options
Products and Services [Axis]
Product Information [Line Items]
Net income (loss)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Estimated useful lives
Property, Plant and Equipment, Estimated Useful Lives
Property, plant and equipment
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment [Abstract]
Property, plant and equipment, net
Total Property, plant and equipment, net
Property, plant and equipment
Property, Plant and Equipment, Gross
Property, plant and equipment
Property, Plant and Equipment Disclosure [Text Block]
Property, Plant and Equipment [Line Items]
Estimated useful lives
Property, Plant and Equipment, Type [Axis]
Property, Plant and Equipment, Type [Domain]
Bad debt expense
Quarterly financial data (unaudited)
Quarterly Financial Information [Text Block]
Quarterly financial data (unaudited) [Abstract]
Range [Domain]
Range [Axis]
Receivables Billing Status [Domain]
Accounts receivable [Abstract]
Gross unrecognized tax benefits activity [Roll Forward]
Percentage of net sales of biodefense products subject to payment to related party
Costs incurred from services rendered under marketing/consulting agreement
Related Party Transaction [Line Items]
Related party transactions
Related Party Transactions Disclosure [Text Block]
Related party transactions [Abstract]
Expenses incurred under agreement
Payments of notes payable
Repayments of Notes Payable
Research and Development [Member]
Research and Development Expense [Member]
Research and development
Research and Development Expense, Policy [Policy Text Block]
Research and Development Tax Credit [Member]
Research and development
Restricted Stock Units (RSUs) [Member]
Restricted cash
Restructuring Plan [Axis]
Restructuring Plan [Domain]
Expenses incurred
Restructuring Charges
Other adjustments
Restructuring
Restructuring Type [Axis]
Restructuring [Abstract]
Balance, end of period
Balance, beginning of period
Restructuring Reserve
Summary of activity for liabilities [Roll Forward]
Restructuring Cost and Reserve [Line Items]
Incurred costs
Retained earnings
Retained Earnings [Member]
Revenue Recognition [Abstract]
Revenue recognition
Revolving Credit Facility [Member]
Subsegments [Axis]
Subsegments [Domain]
Contractual life of awards
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Aggregate intrinsic value [Abstract]
Expected average life of options
Outstanding, beginning of period
Outstanding, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Weighted average remaining contractual term of options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Exercisable, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Weighted average remaining contractual term of options outstanding
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Future Amortization Expense
Revenues:
Product sales
Total revenues
Revenue
Revenue [Member]
Scenario, Unspecified [Domain]
Forecast [Member]
Option award activity
Net deferred tax asset
Gross unrecognized tax benefits activity
Summary of basic and diluted net income per share
Schedule of Operating Leased Assets [Table]
Reconciliation of taxes determined by applying U.S. federal statutory rate to loss before provision for income taxes
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule of Product Information [Table]
Schedule of Product Information [Table]
Inventories
Schedule of Inventory, Current [Table Text Block]
Restricted stock units activity
Assumptions used in valuing stock options granted
Allocation of purchase price based upon estimated fair values of assets acquired and liabilities assumed
Future Minimum Lease Payments under Operating Lease Obligations
Quarterly financial information
Components of the provision for income taxes attributable to operations
Summary of total purchase price
Intangible Assets
Schedule of Business Acquisitions, by Acquisition [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Summarized results of discontinued operations included in consolidated statements of income
Disposal Groups, Including Discontinued Operations [Table Text Block]
Allocated stock-based compensation expense
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]
Goodwill
Schedule of Goodwill [Table Text Block]
Schedule of Restructuring and Related Costs [Table]
Summary of the activity for liabilities related to EBOL restructuring
Schedule of Related Party Transactions, by Related Party [Table]
Costs of the restructuring
Property, Plant and Equipment [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Schedule II - Valuation and Qualifying Accounts
Accounts receivable
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table]
Segment information
Segment Reporting Disclosure [Text Block]
Segment information [Abstract]
Segment Reporting Information [Line Items]
Discontinued Operations [Member]
Operating Activities [Domain]
Geographical [Domain]
Geographical [Domain]
Continuing Operations [Member]
Selling, General and Administrative [Member]
Selling, General and Administrative Expenses [Member]
Selling, general and administrative
Selling, General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)
Equitable adjustment (in dollars per share)
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-Average Grant Price [Roll Forward]
Exercised (in dollars per share)
Stock-based compensation expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Weighted-Average Exercise Price [Roll Forward]
Cancelled (in dollars per share)
Forfeited (in dollars per share)
Granted (in dollars per share)
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Exercisable, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Expected dividend yield
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Granted (in shares)
Expected volatility
Outstanding, end of period (in dollars per share)
Outstanding, beginning of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Risk-free interest rate
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Assumptions used in valuing the stock options granted [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Common stock available for future awards (in shares)
Exercisable, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Common stock authorized for issuance under the plan (in shares)
Restricted stock unit award activity [Roll Forward]
Total intrinsic value of options exercised
Equitable adjustment (in shares)
Outstanding, end of period
Outstanding, beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Options expected to vest, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Weighted average grant date fair value of options granted (in dollars per share)
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Outstanding, end of period (in dollars per share)
Outstanding, beginning of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Options expected to vest, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Options expected to vest, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Options outstanding [Roll Forward]
Cancelled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Award Type [Domain]
Accounting for stock-based compensation
Summary of significant accounting policies
Significant Accounting Policies [Text Block]
Termination Benefits [Member]
State and Local Jurisdiction [Member]
Statement [Line Items]
Consolidated Statement of Changes in Stockholders' Equity [Abstract]
Geographical [Axis]
Consolidated Statements of Cash Flows [Abstract]
Consolidated Statements of Comprehensive Income [Abstract]
Consolidated Balance Sheets [Abstract]
Operating Activities [Axis]
Scenario [Axis]
Statement [Table]
Equity Components [Axis]
Equity Components [Axis]
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Authorized amount for the repurchase program
Employee equity plans activity (in shares)
Shares issued to extinguish convertible notes (in shares)
Shares issued to extinguish convertible notes
Shares issued to extinguish convertible notes
Employee equity plans activity
Repurchased common stock
Treasury stock
Stock Repurchased During Period, Value
Treasury stock (in shares)
Repurchased common stock (in shares)
Stock Repurchased During Period, Shares
Total stockholders' equity
Balance
Balance
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Stockholders' equity:
Separation of Aptevo
Stockholders' equity
Stockholders' equity [Abstract]
Supplemental disclosure of cash flow information:
Tax Credit Carryforward, Name [Domain]
Tax credit carryforwards, expiration date
Tax Credit Carryforward, Expiration Date
Tax Credit Carryforward [Table]
Tax credit carryforward, amount
Tax Credit Carryforward [Axis]
Tax Credit Carryforward [Line Items]
Income taxes payable
Treasury stock, at cost, 1,214,443 and 422,830 common shares at December 31, 2017 and December 31, 2016, respectively
Treasury Stock, Value
Treasury Stock [Member]
Treasury stock (in shares)
Type of Restructuring [Domain]
Type of Adoption [Domain]
Unbilled [Member]
Increases for tax positions for prior years
Increases for tax positions for current year
Decreases for tax positions for prior years
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Lapse of statute of limitations
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Settlements
Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities
Gross unrecognized tax benefits, beginning balance
Gross unrecognized tax benefits, ending balance
Unrecognized Tax Benefits
Unsecured debt
Unsecured Debt
Use of estimates
Charged to costs and expenses
Beginning Balance
Ending Balance
Valuation Allowances and Reserves, Balance
Valuation Allowances and Reserves [Domain]
Valuation and Qualifying Accounts Disclosure [Table]
Valuation Allowances and Reserves Type [Axis]
Schedule II - Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts Disclosure [Line Items]
Deductions
Variable Rate [Domain]
Variable Rate [Axis]
Weighted-average number of shares - basic (in shares)
Weighted-average number of shares-basic (in shares)
Weighted-average number of shares - diluted (in shares)
Weighted-average number of shares-diluted (in shares)
Denominator [Abstract]
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
United Arab Emirates [Member]
Qatar [Member]
Saudi Arabia [Member]
Revenue earned during the period arising from manufacturing sale under the terms of a contract.
Contract manufacturing
Refers to NuThrax which is sold by the company.
Biothrax [Member]
BioThrax [Member]
Refers to foreign jurisdictions.
ForeignJurisdictions [Member]
Foreign Jurisdictions [Member]
Refers to the number of publicly traded companies into which entity is separated.
Number of Independent Public Traded Entities
Number of independent publicly-traded companies
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a non-current liability as of the balance sheet date.
Unrecognized tax benefits, noncurrent
The gross amount of unrecognized tax benefits pertaining to uncertain tax positions taken in tax returns, and classified as a current liability as of the balance sheet date.
Unrecognized tax benefits, current
The portion of profit or loss for the period, net of income taxes and other adjustments.
Adjusted net loss
Net income, adjusted
The portion of profit or loss for the period, adjusted from continuing operations.
Net income, adjusted from continuing operations
Net income, adjusted from continuing operations
The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations before purchase price adjustment.
Deferred Income Tax Expense (Benefit) before purchase price adjustment
Total deferred
Disclosure of information about income taxes.
Income Tax Disclosure [Table]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Income Tax Disclosure [Line Items]
Income Tax Disclosure [Line Items]
Amount of reasonable estimate for income tax expense (benefit) from effect of Tax Cuts and Jobs Act of 2017 for which accounting for tax effect is incomplete.
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit
Provisional tax benefit
Amount of reasonable estimate for income tax expense from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act of 2017 for which accounting for tax effect is incomplete.
Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense
Provisional tax expense
Amount of reasonable estimate for undistributed accumulated earnings of foreign subsidiary intended to be permanently reinvested outside country of domicile for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act of 2017.
Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Provisional Undistributed Accumulated Earnings of Foreign Subsidiary
Estimated undistributed foreign E&P
Period for U.S. federal cash taxes reasonable estimate for income tax expense (benefit) from effect of Tax Cuts and Jobs Act of 2017 for which accounting for tax effect is incomplete, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Tax Cuts and Jobs Act of 2017, Incomplete Accounting, U.S. Federal Cash Taxes on Deemed Mandatory Repatriation Period
U.S. federal cash taxes on deemed mandatory repatriation period
The cash outflow associated with regulatory related milestones.
Amount of payment for regulatory related milestones
Business acquisition in October of 2017.
ACAM2000 [Member]
Business acquisition in December 2014 and December 2015
Evolva Holding SA 035 & Unither [Member]
RSDL, a product of HPPD.
RSDL [Member]
Disclosure of accounting policy for contingent consideration obligations.
Contingent Consideration Obligations [Policy Text Block]
Contingent Consideration
Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.
Property, Plant and Equipment Useful Lives [Text Block]
Estimated useful lives of property, plant and equipment
Refers to the number of revenue generating products.
Number of revenue generating products
Refers to the number of categories of public health threats.
Number of categories of public health threats
Carrying value as of the balance sheet date of the current portion of liabilities incurred and payable to former shareholders and stock option holders of Trubion Pharmaceuticals for certain developmental, regulatory or commercial milestones.
Contingent Value Rights Current Portion
Contingent consideration, current portion
Carrying value as of the balance sheet date of the noncurrent portion of liabilities incurred and payable to former shareholders and stock option holders for certain developmental, regulatory or commercial milestones.
Contingent Consideration Net Of Current Portion
Contingent consideration, net of current portion
Amount of cash outflow associated with the distribution of Aptevo common stock.
Distribution of Aptevo
Distribution to Aptevo
Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.
Change In Fair Value Of Contingent Consideration
Change in fair value of contingent obligations
The cash outflow for contingent value rights.
Contingent value right payment
Contingent consideration payments
The provision charged to earnings in the period related to chargebacks obligations.
Provision for chargebacks, charged to earnings
Provision for chargebacks
Increase in noncontrolling interest balance because of non-cash development expenses from joint venture.
Noncontrolling Interest, Noncash development expenses from joint venture
Non-cash development expenses from joint venture
Percentage of the employee's gross salary that is subject to employer's matching contribution.
Defined Contribution Plan, Percentage of Employee Gross Salary Subject to Employer Matching
Percentage of employee's gross salary subject to employer's matching contribution
Revolving credit loan dated in December 2013.
Revolving Credit Loan dated December 2013, due in December 2018 [Member]
BAML Revolving Credit Facility [Member]
Credit agreement dated September 2017.
Credit Agreement [Member]
Debt instrument dated January 2014 due 2021.
Convertible Senior Notes Due 2021 [Member]
2.875% Convertible Senior Notes Due 2021 [Member]
Refers to the BAML Term Loan.
EBS BAML Term Loan [Member]
BAML Term Loan [Member]
The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
Debt Instrument, Number of Equity Instruments
Conversion rate of notes per $1,000 principal amount (in shares)
Number of lending institutions in which the entity has a credit facility.
Number of lending institutions
Minimum cash and liquid investments balance required in order to be in compliance with the covenant clauses of the debt agreement.
Debt instrument covenant, minimum cash and liquid investments balance
Debt covenant, minimum cash and liquid investments balance
A debt service coverage ratio required to be maintained under a debt covenant agreement. The debt coverage ratio is calculated by dividing earnings before interest, taxes, depreciation and amortization for the most recent four quarters less cash taxes by the sum of current obligations and interest expense for borrowed money, in each case due and payable following four quarters.
Debt Instrument, covenant, debt service coverage ratio
Debt covenant, consolidated debt service coverage ratio, minimum
Maximum leverage ratio required to be maintained under a debt covenant agreement. A leverage ratio is calculated by dividing the funded debt by earnings before interest, taxes, depreciation and amortization for the most recent four quarters.
Debt Instrument, covenant, leverage ratio
Debt covenant, leverage ratio, maximum
The number of additional equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
Debt Instrument Number Of Additional Equity Instruments
Additional conversion rate of notes per $1,000 principal amount (in shares)
Amount for accrued, but unpaid interest on the converted notes for the period.
Debt Instrument Accrued interest on converted notes
Accrued interest on converted notes
Refers to line of credit facility additional borrowing capacity through accordion feature.
Line of credit facility, additional borrowing capacity, accordion feature
Borrowing capacity with accordion feature
Amount of debt issuance costs in prepaid and other current assets, netted against long term debt.
Amount of debt issuance costs in prepaid and other current assets, netted against long term debt [Member]
Amount of debt issuance costs in other assets, netted against long term debt.
Amount of debt issuance costs in other assets, netted against long term debt [Member]
Facility held for productive use including, but not limited to, office, production, storage and distribution facilities in Rockville, Maryland.
Fill/Finish Space - Rockville [Member]
Fill/Finish Space - Rockville [Member]
Facility held for productive use including, but not limited to, office, production, storage and distribution facilities in Baltimore, Maryland.
Office and Warehouse Space - Baltimore [Member]
Office and Warehouse Space - Baltimore [Member]
Facility held for productive use including, but not limited to, office, production, storage and distribution facilities in Canton, Massachusetts.
Office and Warehouse Space - Canton [Member]
Office and Warehouse Space - Canton [Member]
Facility held for productive use including, but not limited to, office, production, storage and distribution facilities in Washington, DC.
Office Space - Washington, DC [Member]
Office Space - Washington, DC [Member]
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year net of future sublease income.
Operating Leases, Future Minimum Payments Due Net of Future Sublease Income
Total net minimum lease payments
This element represents the annual escalation percentage of rent payment in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.
Operating Leases, Rent Expense, Annual Escalation Percentage
Annual escalation percentage
SG&A line item for intangible amortization expense
Selling, general and administrative [Member]
Research and development portion of intangible amortization expense
Research and development [Member]
COGS line item for intangible amortization expense
Cost of product sales and contract manufacturing [Member]
Amount of amortization expense expected to be recognized during the fifth fiscal year and after following the latest fiscal year for assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Finite Lived Intangible Assets Amortization Expense Year Five and After
2022 and beyond
A series of molecules included as an IPR&D asset.
EV-035 [Member]
Goodwill, Cost Basis [Abstract]
A component of the Biosciences business segment.
Contract Manufacturing [Member]
A component of the Biodefense segment.
Therapeutics and Vaccines [Member]
A component of the Biodefense segment.
Medical Devices [Member]
Basis of presentation and consolidation [Abstract]
Refers to the term of procurement contract.
Term of procurement contract
Document and Entity Information [Abstract]
A share-based compensation plan adopted by the Company in 2004.
Emergent BioSolutions Employee Stock Option Plan [Member]
2004 Plan [Member]
A share-based compensation plan adopted by the Company in 2006.
Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]
2006 Plan [Member]
Fair value of share-based compensation awards vested. Includes options, share units, stock appreciation rights, and restricted stock.
Share based Compensation Arrangement Share based Payment Award, Awards Vested in Period, Fair Value
Total fair value of awards vested
Refers to the number of equity award plans the Company has.
Number of equity award plans
The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period
Cancelled (in shares)
Equitable adjustment of shares (or other type of equity) under an equity-based award plan, other than a stock option plan during the reporting period.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Other Increases (Decreases) in Period
Equitable adjustment (in shares)
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value
Cancelled (in dollars per share)
Equitable adjustment of weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Equitable Adjustment Weighted Average Grant Date Fair Value
Equitable adjustment (in dollars per share)
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Cash Flow [Table Text Block]
Summary of disposal groups including discontinued operations cash flows
Number of shares received by shareholders due to spin-off.
Number of shares received (in shares)
Number of shares held as of the record date of the spin-off.
Number of shares held (in shares)
Record Date
Record date for distribution
Record date for distribution
Percentage Of Outstanding Shares Distributed
Percentage Of Outstanding Shares Distributed
Percentage of outstanding shares distributed
Disposal Group Not Discontinued Operation Income Statement Sales Revenue [Abstract]
Revenues [Abstract]
Disposal Group Including Discontinued Operation Nonoperating Income Expense [Abstract]
Other income (expense), net [Abstract]
Disposal Group Including Discontinued Operation Operating Expenses [Abstract]
Operating expense [Abstract]
Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Selling General And Administrative Expense
Selling, general and administrative
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts attributable to disposal group, including but not limited to, discontinued operations.
Disposal Group Including Discontinued Operation Sales Revenue Goods Net
Product sales
Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Contracts Revenue
Collaborations
Shares issued in the distribution.
Number of common stock distributed
Number of common stock distributed (in shares)
Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Research And Development
Research and development
Term of manufacturing services contract commencing on the date of distribution.
Term of manufacturing services contract
Term of agreement to provide transitional services following the date of distribution.
Term of transition services agreement
Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Aptevo [Member]
Aptevo [Member]
Amount of revenue from manufacturing services.
Manufacturing services revenue
Restructuring costs related to retention of certain employees.
Retention Payments [Member]
Refers to the number of facilities to be restructured.
Number of facilities
A plan adopted by the Company in August 2016 to restructure and reprioritize the operations of Emergent BioDefense Operations Lansing LLC ("EBOL").
EBOL Restructuring Plan [Member]
Restructuring cost related to abandonment of equipment.
Abandonment of Equipment [Member]
A valuation allowance relating to inventory.
Inventory Allowance [Member]
A valuation allowance relating to prepaid expenses and other current assets.
Prepaid Expenses and Other Current Assets Allowance [Member]
Asset acquisition in October of 2017.
RaxibacumabMember [Member]
Raxibacumab [Member]
Business acquisition in July 2017.
Sanofi [Member]
Business acquisition in July 2017.
GSK [Member]
Term of contract under acquisition.
Term of contract under acquisition
Refers to the value of contract.
Value of contract
Amount for deliveries of product to the Strategic National Stockpile ("SNS").
Amount for deliveries of product
Amount for deliveries of product to the SNS
Refers to upfront payments by the entity.
Upfront Payments
Upfront cash payment
The cash outflow associated with manufacturing related milestones.
Amount of payment for manufacturing related milestones
Period of a change in the nature or conduct of the business following a change in ownership, which changes the life of operating loss carryforwards.
Operating Loss Carryforwards, Period of Change in Nature and Conduct of Business for Changing Life of Operating Loss Carryforwards
Period of change in the nature or conduct of business following change in ownership
Refers to Canadian Federal Scientific Research And Experimental Development.
CanadianFederalScientificResearchAndExperimentalDevelopment [Member]
Canadian Federal Scientific Research And Experimental Development [Member]
Refers to Manitoba Scientific Research And Experimental Development.
ManitobaScientificResearchAndExperimentalDevelopment [Member]
Manitoba Scientific Research And Experimental Development [Member]
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible scientific research and experimental development tax credit carryforwards.
Deferred Tax Assets, Tax Credit Carryforwards, Scientific Research and Experimental Development
Scientific research and experimental development credit carryforward
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Net Operating Loss Carryforward (state)
State losses carryforward
Refers to State and Local Jurisdiction -Tax Effected.
State and Local Jurisdiction -Tax Effected [Member]
State and Local Jurisdiction - Tax Effected [Member]
Refers to U.S. Federal Tax Authority-Tax Effected.
U.S. Federal Tax Authority-Tax Effected [Member]
U.S. Federal Tax Authority - Tax Effected [Member]
Refers to Canadian Federal Gross.
Canadian Federal Gross [Member]
Refers to Canadian Federal Tax Effected.
Canadian Federal Tax Effected [Member]
Refers to Foreign Tax Authority Tax Effected.
Foreign Tax Authority Tax Effected [Member]
Refers to Foreign Tax Authority Tax Effected Excluding Canada.
Foreign Tax Authority Tax Effected Excluding Canada [Member]
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.
Effective Income Tax Rate Reconciliation, Permanent Difference
Permanent differences
Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to increase (decrease) from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act of 2017.
Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act of 2017, Transition Tax on Accumulated Foreign Earnings, Amount
Transition Tax
Refers to NuThrax which is sold by the company.
NuThrax [Member]
Refers to the Biomedical Advanced Research and Development Authority (BARDA).
BARDA [Member]
The amount of consideration allocated to delivery of the drug under the agreement.
Consideration Allocated To Delivery
Consideration allocated to procurement
The amount of consideration allocated to development activities for the drug under the agreement.
Consideration Allocated To Development Activities
Consideration allocated to development activities
Discount on purchase price for doses to be procured.
Discount on purchase price for doses to be procured
Number of doses to be delivered under the contract.
Number of doses to be delivered
Amount of contract with BARDA for the delivery of BioThrax.
Amount of contract
Period of performance for delivery of BioThrax.
Period of performance
Minimum exercise price of option as percentage of the fair market value of the shares underlying such option on the date of grant.
Exercise price of option as percentage of fair market value at grant date, minimum
Exercise price of option as percentage of fair market value at grant date, minimum
Represents the period over which options can be exercised from the date of grant.
Share Based Compensation Arrangement by share Based Payment Award, Options, Exercise Period
Exercise period of options
Represents the number of stock-based compensation plans the company maintains.
Number of stock based employee compensation plans
Number of stock based employee compensation plans
Refers to the Company's two stock-based employee compensation plans, the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan").
Emergent Plans [Member]
Recently Issued Accounting Standards [Abstract]
Recently issued accounting standards [Abstract]
Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to excess tax benefit for share-based compensation cost.
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
Change to estimated effective annual tax rate